Literature DB >> 29493726

Contact allergy to benzalkonium chloride in patients using a steroid nasal spray: A report of 3 cases.

Jérôme René Lechien1, Pedro Costa de Araujo, Lisa G De Marrez, Jean-Luc Halloy, Mohamad Khalife, Sven Saussez.   

Abstract

Benzalkonium chloride (BAC) is a bactericidal preservative excipient commonly found in steroid nasal sprays used to treat allergic rhinitis and nasal polyposis. In rare cases, BAC can be responsible for type I and type IV hypersensitivity reactions that can manifest as rhinorrhea, which a clinician might misinterpret as a lack of response to nasal spray therapy rather than a complication of it. We report 3 cases of type IV hypersensitivity reactions in patients who were being treated with mometasone nasal spray. We describe the epidemiology, clinical features, diagnosis, and treatment of these reactions.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29493726     DOI: 10.1177/0145561318097001-205

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  4 in total

1.  ADR in Journals: Are They Translated into Regulatory Frameworks?

Authors:  Annapurna Kolupoti; Ananya Chakraborty; K Shahistha
Journal:  Curr Drug Saf       Date:  2022

2.  Mitochondrial Dysfunctions May Be One of the Major Causative Factors Underlying Detrimental Effects of Benzalkonium Chloride.

Authors:  Anton G Rogov; Tatyana N Goleva; Evgeniya I Sukhanova; Khoren K Epremyan; Tatiana A Trendeleva; Alexandra P Ovchenkova; Dinara A Aliverdieva; Renata A Zvyagilskaya
Journal:  Oxid Med Cell Longev       Date:  2020-02-10       Impact factor: 6.543

Review 3.  Quaternary ammonium compounds in hypersensitivity reactions.

Authors:  Marine Peyneau; Luc de Chaisemartin; Nicolas Gigant; Sylvie Chollet-Martin; Saadia Kerdine-Römer
Journal:  Front Toxicol       Date:  2022-09-16

4.  Distribution of benzalkonium chloride into the aqueous phases of submicron dispersed systems: emulsions, aqueous lecithin dispersion and nanospheres.

Authors:  Dorota Watrobska-Swietlikowska
Journal:  AAPS PharmSciTech       Date:  2019-12-02       Impact factor: 3.246

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.